CAPSTONE INVESTMENT ADVISORS, LLC - KARYOPHARM THERAPEUTICS INC ownership

KARYOPHARM THERAPEUTICS INC's ticker is and the CUSIP is 48576UAA4. A total of 19 filers reported holding KARYOPHARM THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
CAPSTONE INVESTMENT ADVISORS, LLC ownership history of KARYOPHARM THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$4,654,419
-9.1%
7,500,0000.0%0.02%
-16.0%
Q2 2023$5,118,750
+20.0%
7,500,000
+36.4%
0.02%
+13.6%
Q1 2023$4,263,913
+60.5%
5,500,000
+57.1%
0.02%
+15.8%
Q4 2022$2,656,016
-6.1%
3,500,0000.0%0.02%
+11.8%
Q3 2022$2,828,000
-30.1%
3,500,000
-36.4%
0.02%
-15.0%
Q2 2022$4,046,000
-13.2%
5,500,0000.0%0.02%
+53.8%
Q1 2022$4,660,000
+3.6%
5,500,0000.0%0.01%
+62.5%
Q4 2021$4,496,000
-14.7%
5,500,000
-21.4%
0.01%
-20.0%
Q3 2021$5,268,000
-25.0%
7,000,0000.0%0.01%
-37.5%
Q2 2021$7,021,000
-49.8%
7,000,000
-48.1%
0.02%
-61.0%
Q1 2021$13,992,00013,500,0000.04%
Other shareholders
KARYOPHARM THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
STEELHEAD PARTNERS LLC 16,000,000$16,661,0001.26%
Opti Capital Management, LP 9,000,000$9,367,0001.14%
Context Capital Management, LLC 10,500$10,883,0001.07%
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP 20,000,000$20,429,0000.20%
AQR Arbitrage LLC 4,100,000$4,249,0000.15%
FARALLON CAPITAL MANAGEMENT LLC 25,000,000$25,538,0000.13%
CAPSTONE INVESTMENT ADVISORS, LLC 13,500,000$13,992,0000.04%
LAZARD ASSET MANAGEMENT LLC 22,500,000$23,319,0000.03%
Citadel Advisors 48,300,000$50,405,0000.01%
MACKAY SHIELDS LLC 93,000$96,0000.00%
View complete list of KARYOPHARM THERAPEUTICS INC shareholders